Campbell & CO Investment Adviser LLC Buys New Stake in GeneDx Holdings Corp. $WGS

Campbell & CO Investment Adviser LLC bought a new stake in GeneDx Holdings Corp. (NASDAQ:WGS) in the 2nd quarter, HoldingsChannel reports. The fund bought 2,206 shares of the company’s stock, valued at approximately $204,000.

A number of other large investors have also made changes to their positions in WGS. T. Rowe Price Investment Management Inc. purchased a new stake in shares of GeneDx during the 1st quarter valued at $44,614,000. William Blair Investment Management LLC grew its stake in GeneDx by 37.2% during the 2nd quarter. William Blair Investment Management LLC now owns 1,631,402 shares of the company’s stock worth $150,595,000 after buying an additional 442,414 shares during the last quarter. Alliancebernstein L.P. increased its position in GeneDx by 3,054.5% during the 1st quarter. Alliancebernstein L.P. now owns 436,900 shares of the company’s stock valued at $38,694,000 after buying an additional 423,050 shares in the last quarter. Jennison Associates LLC raised its stake in GeneDx by 6,163.1% in the second quarter. Jennison Associates LLC now owns 397,896 shares of the company’s stock valued at $36,730,000 after buying an additional 391,543 shares during the last quarter. Finally, Wellington Management Group LLP raised its stake in GeneDx by 202.3% in the first quarter. Wellington Management Group LLP now owns 425,647 shares of the company’s stock valued at $37,697,000 after buying an additional 284,855 shares during the last quarter. 61.72% of the stock is owned by institutional investors and hedge funds.

GeneDx Stock Down 2.0%

WGS stock opened at $126.92 on Wednesday. The company has a market capitalization of $3.67 billion, a P/E ratio of 1,410.22 and a beta of 2.01. GeneDx Holdings Corp. has a 12 month low of $55.17 and a 12 month high of $147.71. The firm’s fifty day simple moving average is $126.03 and its 200-day simple moving average is $102.48. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.71 and a quick ratio of 2.59.

GeneDx (NASDAQ:WGS) last posted its earnings results on Tuesday, October 28th. The company reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.28 by $0.21. The company had revenue of $116.74 million during the quarter, compared to the consensus estimate of $104.33 million. GeneDx had a net margin of 0.52% and a return on equity of 20.22%. GeneDx has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on WGS shares. Wall Street Zen lowered GeneDx from a “buy” rating to a “hold” rating in a research note on Saturday, November 1st. Piper Sandler upped their price target on shares of GeneDx from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, September 11th. Zacks Research cut shares of GeneDx from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 2nd. Guggenheim reissued a “buy” rating and set a $170.00 price objective (up from $115.00) on shares of GeneDx in a report on Wednesday, October 29th. Finally, BTIG Research upped their target price on GeneDx from $140.00 to $165.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Seven research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $129.22.

Insider Buying and Selling

In related news, CFO Kevin Feeley sold 388 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The stock was sold at an average price of $136.54, for a total transaction of $52,977.52. Following the sale, the chief financial officer directly owned 3,757 shares of the company’s stock, valued at $512,980.78. This trade represents a 9.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Katherine Stueland sold 2,158 shares of GeneDx stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $136.54, for a total value of $294,653.32. Following the transaction, the chief executive officer owned 3,436 shares of the company’s stock, valued at approximately $469,151.44. This represents a 38.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 556,375 shares of company stock worth $67,569,247 over the last ninety days. 29.60% of the stock is owned by corporate insiders.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.